Navigation Links
FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
Date:3/3/2008

PHILADELPHIA and LONDON, March 3 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK; LSE) today announced that the United States Food and Drug Administration has granted Priority Review for PROMACTA(R) (eltrombopag) for the short-term treatment of patients with chronic idiopathic thrombocytopenic purpura (ITP). PROMACTA is an investigational, once-daily oral treatment that induces the production of cells in the bone marrow to generate platelets, which are critical in minimizing the incidence of bleeding in chronic ITP.

If approved, PROMACTA would be the first oral thrombopoeitin (TPO) receptor agonist for the short-term treatment of previously treated patients with chronic ITP to increase platelet counts and reduce bleeding.

"Our goal for PROMACTA is to make available a targeted therapy in oral form for patients to help raise their platelet counts without having to suppress the immune system," said Paolo Paoletti, M.D., Senior Vice President of the Oncology Medicine Development Center at GSK. "The FDA designation of our submission for priority review is very encouraging and brings us closer to offering physicians and their patients PROMACTA."

The priority review designation means FDA is expected to make a decision on the NDA for the investigational compound within six months of the submission.

In pivotal studies, the most common adverse events observed in patients taking PROMACTA were headache, nausea, nasopharyngitis, diarrhea and vomiting.

GSK also plans to submit a Marketing Authorization Application (MAA) for eltrombopag in the treatment of chronic ITP in Europe in 2008 where it will be marketed as REVOLADE(R). The compound is also being studied for long-term treatment of chronic ITP, as w
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
2. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
3. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
4. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
5. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
6. Chinese SFDA Grants Immtech Fast Track Status
7. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
8. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
9. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
10. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
11. FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the second quarter ending June 30, 2015. ... the organization.  We are excited to be near the ... ever conducted with topline results expected in the fourth ... PTC Therapeutics, Inc. "Translarna is now commercially available in ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, modernized ... ingredients (API), provided updates regarding the notice it received ... (the "Exchange") indicating that the Company was below certain ... in Sections 134 and 1101 of the NYSE MKT ...
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... University of Alabama at Birmingham (UAB) Health System became ... to utilize intrafraction motion review (IMR), or "triggered imaging," ... cancer.  IMR, which is a unique capability of the ... VAR ) enables visual verification that a tumor ...
... N.J., Nov. 21, 2011  Omthera Pharmaceuticals, Inc., a ... Jerry Wisler, President and Chief Executive Officer, will ... Piper Jaffray Health Care Conference on Wednesday, November ... York Palace hotel. About Omthera ...
Cached Medicine Technology:Clinicians at the University of Alabama at Birmingham (UAB) Health System First in World to Use "Triggered Imaging" Technology From Varian Medical Systems 2Clinicians at the University of Alabama at Birmingham (UAB) Health System First in World to Use "Triggered Imaging" Technology From Varian Medical Systems 3
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... The need ... In an effort to provide comfort to patients as well as visiting friends and ... solution: free phone charging stations. , The stations - powered by ChargeItSpot , ...
(Date:7/30/2015)... ... July 30, 2015 , ... Ross A. Clevens, MD, FACS has ... Professor of Plastic Surgery. This is Dr. Clevens’ second appointment by the prestigious ... university, developing a strong presence and a valuable mentoring program for medical students. ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... the latest issue of Inclusive™ magazine, its multimedia publication focused on implant dentistry, ... of the new issue, Volume 6, Issue 2, as well as past issues ...
(Date:7/30/2015)... ... July 30, 2015 , ... Boston ... the annual All-Stars Summit. Google Partners is the platform for search marketing agencies ... full support and tools necessary to run successful search marketing campaigns. Google Partners ...
(Date:7/30/2015)... Wisconsin (PRWEB) , ... July 30, 2015 , ... Quintessa ... Kybella is a nonsurgical treatment designed specifically for the elimination of ... one of the first locations in the state of Wisconsin to offer this innovative ...
Breaking Medicine News(10 mins):Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2
... function problems in ill veterans , , TUESDAY, March 24 ... 1991 Gulf War appears to have triggered abnormal responses ... found. , They say the discovery could lead to ... Gulf War syndrome. , The study, from the ...
... eating fish, study finds , , TUESDAY, March 24 (HealthDay ... against advanced prostate cancer, researchers report. , Eating fish ... of developing advanced prostate cancer even if one is ... is needed to see if the association is real, ...
... against advanced prostate cancer, and this effect may be ... according to a report in Clinical Cancer Research ... Research. , "Previous research has shown protection against prostate ... to show protection against advanced prostate cancer and interaction ...
... YORK, March 24, 2009 Researchers may have found a more ... history of the deadly skin disease. In a new study, scientists ... to a nearly four-fold increase of melanoma in women under the ... 24, 2009, in the journal Clinical Cancer Research and ...
... WASHINGTONThe World Health Organization released staggering new data about the ... with HIV/AIDS today, in recognition of World TB Day. ... previously thought, the new WHO figures show. In 2007, there ... 15 percent of the total incident cases. That,s double the ...
... students who are problem drinkers using alcohol to cope ... to continue excessive drinking into adulthood, a recent study ... that adults who are still high-risk drinkers by age ... social and cognitive development that typically occurs during college, ...
Cached Medicine News:Health News:Gulf War Syndrome May Stem From Chemical Exposure 2Health News:Omega-3 Fatty Acids Guard Against Advanced Prostate Cancer 2Health News:Omega-3 Fatty Acids Guard Against Advanced Prostate Cancer 3Health News:NYU study finds new risk factor for melanoma in younger women 2Health News:NYU study finds new risk factor for melanoma in younger women 3Health News:Alarming new data shows TB-HIV co-infection a bigger threat 2Health News:Study helps identify college drinkers who might continue excessive drinking as adults 2Health News:Study helps identify college drinkers who might continue excessive drinking as adults 3Health News:Study helps identify college drinkers who might continue excessive drinking as adults 4Health News:Study helps identify college drinkers who might continue excessive drinking as adults 5
The Trilogy system builds on the success of the Harris/Galante Porous and HGP II cups by combining proven features with new technology designed to inhibit the formation and migration of polyethylene ...
The Secur-Fit cups incorporate enhancements derived from years of clinical, radiographic, and implant retrieval observations....
The Bofor acetabular revision cup addresses cases of severe acetabular destruction....
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Medicine Products: